Our Team

Board of Directors

Tony H NounTony H Noun
Director/Executive Chairman

MBA; FAIM; CFP; CIAM; DipLi; DipAII; Aff&CIP ANZIP; AFA; JP

Tony has more than 20 years professional and commercial experience with a proven track record of success. Currently, he is not only the Chairman of the Northern Cancer Institute group, but also a public company and a substantive number of other private companies that include, an Australian Financial Services License holder and specialist Healthcare Management Consultancy Practice.

Tony's commercial experience, from both an investor and manager perspective, spans a diverse range of disciplines and thus, brings extensive healthcare, financial and corporate experience to lead the Board and Management of Northern Cancer Institute to provide its patients with Excellence in Care.

Assoc Professor Nick PavlakisNick Pavlakis
Director, Assoc Prof

A/Prof Nick Pavlakis underwent undergraduate medical training at the University of NSW and graduated in 1991. He underwent general medical training and subsequent advanced training in Medical Oncology at Royal North Shore Hospital, completing FRACP in 1997. He then spent 3 years completing a PhD in new cancer drug development involving an Australian developed anti-angiogenic compound PI-88 (Progen Industries and ANU); and a Masters of Clinical Epidemiology through the University of Sydney. He has worked in private oncology practice since 1998 and has been a practice member of the Northern Cancer Institute since 2001. He is current Chair of the Lung Cancer Group of the Clinical Oncologic Society for Australa (COSA), and is Regent for Australasia for the International Association for the Study of Lung Cancer (IASLC).

He is an academic medical oncologist, having published journal manuscripts in his interest areas (lung cancer, mesothelioma, NETS, kidney cancer, gastric cancer, colorectal cancer and bisphosphonate therapy, is conducting ongoing collaboratve clinical research ((Australasian Gastro-intestinal Trials Group (AGITG), ALTG,  Australia and NZ Urologic and Prostate Cancer Trials Group (ANZUP)) and translational research with the Bill Walsh Cancer Research Laboratories/Kolling Institute.

Associate Professor David BellDavid Bell
Director

Associate Prof. David Bell is currently Senior Staff Specialist, Medical Oncology at Royal North Shore Hospital with responsibility for the Medical Oncology Unit. Malignancies include breast, lung, colon and rectum, testicular, sarcoma, renal, melanoma, lymphoma, head and neck and brain.

He is a Visiting Medical Oncologist at North Shore Private Hospital, Manly Waters Private and Armidale Base Hospital.

Dr Bell is also Clinical Senior Lecturer in Medicine at the University of Sydney and has conducted both clinical and laboratory research work which has been widely published. He is also Associate Professor in Rural medicine at the University of New England. He is principle researcher in numerous studies covering aspects of lung, breast, ovarian, soft tissue, skin and renal cancer as well as investigations of multidrug resistance and drugs of potential patient benefit.

Dr Bell has been an invited speaker at numerous national and international forums including the USA, Canada, Hong Kong, Singapore, France and Germany.

Greg BrownGreg Brown
Director

Greg Brown is the CEO of North Shore Private Hospital and Castlecrag Private Hospital, a position which he had held since August 2004.

Greg began his career in accounting, where exposure to hospital audits had developed an interest in health. His first involvement in the health sector was at Dubbo Base Hospital in June of 1975. Greg spent a number of years managing Radiology Practices as well as a group of GP Medical Centres, providing Greg with a very good insight into the importance of communication between the GP, the Specialist, the Private Hospital and the Pathology/Radiology providers.

Greg has held senior management roles for the past 32 years starting as the Deputy CEO at Gunnedah District Hospital progressing to the same role at Hastings District Hospital in Port Macquarie. Greg commenced his career in the Private sector as CEO of Warner's Bay Private Hospital in 1986 and for the next 10 years held similar positions at Christo Road, Mosman, St Margaret's Peninsula and Bankstown Private Hospitals before taking a slight career change when he was appointed the General Manager of the GeRadiology, Pathology and General Practice Division of AlphaHealthcare. After spending a number of years in this role, Greg was appointed to the role of General Manager Radiology Central Qld, ACT and Joint Ventures for MIA.

Greg is a Director of the Kolling Foundation, the Sydney Neuro Oncology Group, the Lincoln Centre, the North Shore Heart Research Foundation and the Northern Cancer Institute.

Dominic MayDominic May
Director

MMGT, JP
Dominic May is a Commercial Manager at North Shore Private Hospital St Leonards and is a member of the hospital Executive Team. His primary responsibility is to oversee the commercial obligations at North Shore Private Hospital and to contribute to the efficient and professional performance of the hospital through his contribution as a member of the hospital Executive Team.

He has attained a Master of Management through the Macquarie University Graduate School of Management - MGSM.

Dominic has over 30 years commercial management experience in industries including Private Health Care, Medical & Scientific Research, International Trade Finance, Corporate & Commercial Banking & the Australian Wine Industry.

Professor Stephen ClarkeStephen Clarke
Alternate Director to David Bell

Stephen Clarke is a medical oncologist, pharmacologist and translational researcher with major clinical and research interests in gastrointestinal and thoracic cancers and pharmacology. He is a medical oncologist at the Northern Cancer Institute and Royal North Shore Hospital, Director of Cancer Services at Northern Sydney Local Health District and Professor of Medicine at the University of Sydney.

Prof Clarke completed his medical degree at the University of Sydney in 1983 and an FRACP in Medical Oncology at Royal North Shore Hospital in 1990. He then completed a PhD at the University of London at the Institute of Cancer Research / Royal Marsden Cancer Hospital. Professor Clarke returned from the UK in 1994 and has worked at Westmead, Nepean, Concord and Royal Prince Alfred Hospitals prior to returning to Royal North Shore Hospital in 2010. He obtained an MD from the University of Sydney in 2011.

Stephen was awarded an OAM in the Australia Day Honours in 2011 for services to medicine in the disciplines of oncology and pharmacology. He was also awarded the Eric Susman Prize from the Royal Australasian College of Physicians in 2013. In 2015 he was elected to the newly created Australian Academy of Health and Medical Science. He was also elected to be an inaugural member of Best Doctors in Australia and New Zealand in 2012.

Stephen is Head of the NSW committee of the RACP and is Oncology Advisor to the Department of Veterans Affairs as well as a Member of the Repatriation Pharmaceutical Review Committee. He has received over $25 million in competitive research funding, which has produced over 260 publications, leading to more than 10000 citations.

Meredith CumminsMeredith Cummins
Director of Nursing / Alternate Director to Tony Noun

Meredith, who has over 23 years of experience in the field of Oncology – public and private sectors, metropolitan, rural, and currently serves as Director of Nursing and Principal Consultant with the Northern Cancer Institute, which are two cancer treatment units where holistic care is given in environments that are designed to be as pleasant and comfortable as possible. Meredith is responsible for all practice accreditation and licensing as well as human resource management, and the administration of chemotherapy treatments.

During her collegiate career, Meredith earned Graduate Certificates in Oncology and Clinical Management from the New South Wales College of Nursing. She is a member of the Cancer Nurses Society of Australia (CNSA), Clinical Oncological Society of Australia (COSA), Australasian Gastrointestinal Trials Group AGITG), Australian Lung Trials Group (ALTG), and the International Association for the Study of Lung Cancer.

Sally Baron-HaySally Baron-Hay
Alternate Director to Nick Pavlakis

Dr Baron-Hay is physician whose main area of interest is in the management of patients diagnosed with breast and gynaecological malignancies.

She participates in the Multidisciplinary care of theses malignancies attending weekly multidisciplinary meetings. These meetings are attending also by radiologists, pathologists, surgeons, radiotherapists, clinical nurse specialists and allied health care professionals.

Her laboratory research interests are discovering new biomarkers of ovarian cancer and their prognostic significance. She also actively participates in clinical trials in breast and gynaecological malignancies. These trials involve the use of new drugs investigating activity in these malignancies as well as trials designed to improve the quality of life of patients. She is actively involved in teaching, both medical students and allied health professional. 

Dr Baron-Hay has admitting rights to North Shore Private Hospital and administers chemotherapy treatments through the Northern Cancer Institute at the hospital.